Welcome > Support > Âü°íÀÚ·á  
 
 
E
 
±Ûº¸±â
¼º¸í ÆijªÁø     (Date : 2016-07-13 10:19:11)
Á¦¸ñ [³í¹®] [2013]Detection of EGFR mutations in circulating free DNA by PNA-mediated PCR clamping.
³»¿ë


J Exp Clin Cancer Res. 2013 Aug 9;32(1):50. doi: 10.1186/1756-9966-32-50.

Detection of EGFR mutations in circulating free DNA by PNA-mediated PCR clamping.

Kim HRLee SYHyun DSLee MKLee HKChoi CMYang SHKim YCLee YCKim SYJang SHLee JCLee KY.

Abstract

BACKGROUND:

Epidermal growth factor receptor (EGFR)-activating mutations are major determinants in predicting the tumor response to EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC). Noninvasive test for the detection of EGFR mutations is required, especially in NSCLC patients from whom tissue is not available. In this study, we assessed the feasibility of detection of EGFR mutations in free DNA circulating in plasma.

METHODS:

Plasma samples of 60 patients with partial response to gefitinib were analyzed to detect EGFR-activating mutations in exons 19 and 21. Forty (66.7%) of patients had tumor EGFR mutation results. EGFR mutations in plasma were detected using the peptide nucleic acid (PNA)-mediated polymerase chain reaction (PCR) clamping method. All clinical data and plasma samples were obtained from 11 centers of the Korean Molecular Lung Cancer Group (KMLCG).

RESULTS:

Of the 60 patients, 39 were female and the median age was 62.5 years. Forty-three patients never smoked, 53 had adenocarcinomas, and seven had other histologic types. EGFR-activating mutation was detected in plasma of 10 cases (exon 19 deletion in seven and exon 21 L858R point mutation in three). It could not be found in plasma after treatment for 2 months. When only patients with confirmed EGFR mutation in tumor were analyzed, 17% (6 of 35) of them showed positive plasma EGFR mutation and the mutation type was completely matched with that in tumor. There was no statistically significant difference in clinical parameters between patients with EGFR mutations in plasma and those without EGFR mutations.

CONCLUSIONS:

The detection rate of EGFR mutations from plasma was not so high despite highly sensitive EGFR mutation test suggesting that more advances in detection methods and further exploration of characteristics of circulating free DNA are required.


 

 ¹øÈ£   Á¦¸ñ ÀÛ¼ºÀÚ ÆÄÀÏ Á¶È¸
   49           [³í¹®] [2016]Comparison of EGFR .. ÆijªÁø 30435
   48           [³í¹®] [2015]IDH Mutation Analys.. ÆijªÁø 65535
   47           [³í¹®] [2015]Low frequency of KR.. ÆijªÁø 29340
   46           [³í¹®] [2015]Simultaneous genoty.. ÆijªÁø 6198
   45           [³í¹®] [2014]Simultaneous diagno.. ÆijªÁø 21104
   44           [³í¹®] [2014]KRAS Mutation Detec.. ÆijªÁø 8545
¢º           [³í¹®] [2013]Detection of EGFR m.. ÆijªÁø 1305
   42           [³í¹®] [2013]Detection and compa.. ÆijªÁø 5946
   41           [³í¹®] [2013]Detection of BRAF V.. ÆijªÁø 6228
   40           [³í¹®] [2013]Comparison of Direc.. ÆijªÁø 25415
   39           [³í¹®] [Microarray]Peptide nucle.. ÆijªÁø 14452
   38           [³í¹®] [Clamp]Rapid and Sensitiv.. ÆijªÁø 22372
   37           [³í¹®] [ÆijªÁø Á¦Ç°»ç¿ë ³í¹®] EGFR µ¹¿¬º¯.. ÆijªÁø 3517
   36           [³í¹®] [ÆijªÁø Á¦Ç°»ç¿ë ³í¹®] Development .. ÆijªÁø 14289
   35           [³í¹®] [ÆijªÁø Á¦Ç°»ç¿ë ³í¹®] JHDM3A modul.. ÆijªÁø 1297
   34           [³í¹®] [PNA Chip vs DNA Chip ÀÓ»ó.. ÆijªÁø 4158
   33           [³í¹®] [ÆijªÁø ³í¹®¹ßÇ¥] PNA-mediated Re.. ÆijªÁø 8953
   32           [³í¹®] [ÆijªÁø Á¦Ç°»ç¿ë ³í¹®] ºñ¼Ò¼¼Æ÷Æó¾Ï¿¡.. ÆijªÁø 14607
   31           [³í¹®] [ÆijªÁø ³í¹® ¹ßÇ¥] PNA-Based Anti.. ÆijªÁø 1300
   30           [³í¹®] [ÆijªÁø ³í¹®¹ßÇ¥]Peptide nucleic .. ÆijªÁø 4022
 

< 1 2 3 >